HauerHA, BajemaIM, van HouwelingenHC, FerrarioF, NoëlLH, WaldherrR, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int, 2002; 61(1):80–89.
KhanSA, SublaMR, BehlD, SpecksU, AfessaB. Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest, 2007; 131(4):972–976.
4.
AllenbachY, SerorR, PagnouxC, TeixeiraL, GuilpainP, GuillevinL. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis, 2009; 68(4):564–567.
5.
MerkelPA, LoGH, HolbrookJT, TibbsAK, AllenNB, DavisJCJr, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med, 2005; 142(8):620–626.
6.
MukhtyarC, GuillevinL, CidMC, DasguptaB, de GrootK, GrossW, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis, 2009; 68(3):310–317.
7.
HarperL, MorganMD, WalshM, HoglundP, WestmanK, FlossmannO, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis, 2012; 71(6):955–960.
8.
StoneJH, MerkelPA, SpieraR, SeoP, LangfordCA, HoffmanGS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med, 2010; 363(3):221–232.
9.
JayneDR, GaskinG, RasmussenN, AbramowiczD, FerrarioF, GuillevinL, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol, 2007; 18(7):2180–2188.
10.
CasianA, JayneD. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol, 2011; 23(1):12–17.
11.
AydinZ, GursuM, KaradagS, UzunS, TatliE, SumnuA, et al. Role of plasmapheresis performed in hemodialysis units for the treatment of anti-neutrophilic cytoplasmic antibody-associated systemic vasculitides. Ther Apher Dial, 2011; 15(5):493–498.
12.
SugimotoT, DejiN, KumeS, OsawaN, SakaguchiM, IsshikiK, et al. Pulmonary-renal syndrome, diffuse pulmonary hemorrhage and glomerulonephritis, associated with Wegener's granulomatosis effectively treated with early plasma exchange therapy. Intern Med, 2007; 46(1):49–53.
13.
ThilleAW, ContouD, FragnoliC, Córdoba-IzquierdoA, BoissierF, Brun-BuissonC. Non-invasive ventilation for acute hypoxemic respiratory failure: intubation rate and risk factors. Crit Care, 2013; 17(6):R269.
14.
SebastianJK, VoetschB, StoneJH, Romay-PenabadZ, LoGH, AllenNB, et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol, 2007; 34(12):2446–2450.
15.
DreyerG, FanS. Therapeutic implications of coexisting severe pulmonary hemorrhage and pulmonary emboli in a case of Wegener granulomatosis. Am J Kidney Dis, 2009; 53(5):e5–e8.
16.
HughesM, BurgessJ, ParekhN. Wegener's granulomatosis complicated by pulmonary embolism: a case report and review of the literature. Mod Rheumatol, 2011; 21(2):211–214.
17.
JaffMR, McMurtryMS, ArcherSL, CushmanM, GoldenbergN, GoldhaberSZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation, 2011; 123(16):1788–1830.
